In this study, we investigated low-frequency and rare variants associated with blood pressure (BP) by focusing on a linkage region on chromosome 16p13. We used whole genome sequencing (WGS) data obtained through the NHLBI Trans-Omics for Precision Medicine (TOPMed) program on 395 Cleveland Family Study (CFS) European Americans (CFS-EA). By analyzing functional coding variants and non-coding rare variants with CADD score > 10 residing within the chromosomal region in families with linkage evidence, we observed 25 genes with nominal statistical evidence (burden or SKAT p < 0.05). One of the genes is RBFOX1, an evolutionarily conserved RNA-binding protein that regulates tissue-specific alternative splicing that we previously reported to be associated with BP using exome array data in CFS. After follow-up analysis of the 25 genes in ten independent TOPMed studies with individuals of European, African, and East Asian ancestry, and Hispanics (N = 29,988), we identified variants in SLX4 (p = 2.19 × 10 −4 ) to be significantly associated with BP traits when accounting for multiple testing. We also replicated the associations previously reported for RBFOX1 (p = 0.007). Follow-up analysis with GTEx eQTL data shows SLX4 variants are associated with gene expression in coronary artery, multiple brain tissues, and right atrial appendage of the heart. Our study demonstrates that linkage analysis of family data can provide an efficient approach for detecting rare variants associated with complex traits in WGS data.
Introduction
Blood pressure (BP) is a complex trait that has been widely studied in genome-wide association studies (GWAS) (International Consortium for Blood Pressure Genome-Wide Association et al. 2011; Levy et al. 2009; Liang et al. 2018; Sung et al. 2018; Warren et al. 2017; Zhu and Cooper 2007; Zhu et al. 2005 Zhu et al. , 2011 Zhu et al. , 2015 . High blood pressure or hypertension is a major modifiable risk factor for cardiovascular disease and an important risk factor for stroke and kidney disease. Family and twin studies suggest 30-50% of the variation in BP is attributable to genetic heritability (Cooper et al. 2002; Kupper et al. 2005; Miall and Oldham 1963; van Rijn et al. 2007 ). To date, over 900 loci have been identified to be associated with BP, accounting for nearly 6% of the heritability of this trait (Evangelou et al. 2018; Hoffmann et al. 2017; Liu et al. 2016a ). However, rare variants are not well examined by GWAS due to their poor tagging by common variants. When multiple rare variants contribute to inter-individual trait variation, these rare variants can be enriched through ascertainment of families (Jun et al. 2018; Zhu et al. 2010) . Correspondingly, linkage analysis of family data is a valid and promising approach for detecting genetic signals because it is insensitive to allelic heterogeneity and facilitates the discovery of missing heritability due to rare variants (Ott et al. 2015) . Using this approach, we identified multiple low-frequency and rare variants in several genes on chromosome 16 contributing to BP variation using exome array data (He et al. 2017) , further demonstrating that family-based study designs are valuable for identifying rare variants.
We reexamined a previously identified BP linkage region on chromosome 16 using whole genome sequencing (WGS) data from the National Heart, Lung, and Blood Institute's (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program. The 16p13 linkage region was initially identified in European Americans from the Cleveland Family Study (CFS), which included 517 individuals in 130 families, genotyped with the Illumina OmniExpress Exome array (focused on protein-coding regions of the genome) (He et al. 2017) . We utilized a two-stage approach in this study ( Fig. 1 ): stage I is the discovery of single variants as well as signals from gene-based tests in the discovery cohort and stage II is the independent external replication. Here, we report association analysis in 30,383 individuals aged 18-91 years at collection, with deep coverage WGS and harmonized BP measurements.
Materials and methods

Study population
The TOPMed program is sponsored by the NHLBI and generates data from multiple omics platforms aimed to improve our understanding of the underlying biological mechanisms for heart, lung, blood, and sleep disorders. TOPMed generated WGS data on all contributed samples with a target of 30x coverage on average. WGS provides a comprehensive view of the human genome; thus, these data offer an unprecedented resource to study the genetic architecture of many heart, lung, blood, and sleep disorders. We used the CFS European American samples (CFS-EA; N = 395; 116 families) for discovery analysis in stage I. All of these families were also in the exome array data for the original linkage analysis and 390 subjects were in both exome array and TOPMed WGS. In stage II, independent replication was performed in ten TOPMed studies (18 ancestry-and study-specific cohorts). These ten studies (N = 29,988) . These studies vary in design: ARIC, JHS, and MESA are community-based studies; Amish, CFS, FHS, GeneSTAR, GenSalt, and HyperGEN_GENOA are familybased studies; and WHI is a population-based cohort study in which a case-control sample was selected for TOPMed. The study was approved by the institutional review board (IRB) at Case Western Reserve University. Each individual cohort study was approved by the appropriate IRB in the corresponding institute and appropriate informed consent was obtained from human subjects for participation in the study.
Quality control
We included only biallelic single nucleotide polymorphisms (SNPs) and insertion-deletion polymorphisms (indels) that passed all filters and had a Phred-scaled quality score (QUAL) > 127, following the quality control (QC) procedures performed centrally by the TOPMed Sequencing Centers, the Informatics Research Center (IRC), and the Data Coordinating Center (DCC). Genotypes for all individuals at all sites passing QC have a minimum 10 × sequencing depth. We included participants from ten TOPMed studies from the freeze_5b release (aligned to GRCh38) and retained only unique subjects that the DCC reported to have no currently known identity problems, reflecting the December 1, 2017 sample annotation. We further restricted our analyzed sample to individuals who were at least 18 years old at time of measurement and excluded principal component (PC) outliers. The PCs were calculated by the TOPMed DCC using the PC-AiR method, which makes robust population structure inference in the presence of known or cryptic relatedness (Conomos et al. 2015) . We included only individuals whose harmonized blood pressure measurements were available for our analysis, resulting in a combined sample size of N = 30,383.
Phenotype harmonization
Phenotype data were collectively harmonized by members of the TOPMed Blood Pressure Working Group. Inclusion criteria for phenotype harmonization include: (1) resting/sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) recorded as part of a research examination, (2) at least two BP measurements were made, and (3) availability of information on the use of antihypertensive medication. With the exception of CFS that utilized data from its last longitudinal examination, when measurements were most comprehensive, all other studies reported measurements from their baseline examinations. For studies with two BP measurements at the baseline visit, the average of the first and second measurements was reported. Studies with three or more BP measurements at baseline reported the average of the second and third measurements. For each of the 19 ancestry-and study-specific cohorts analyzed, we used harmonized SBP and DBP values and for those reporting current use of antihypertensive medication (32% of study subjects), we added 15 mmHg to their SBP and 10 mmHg to their DBP (Law et al. 2009 ). Pulse pressure (PP) was calculated as the difference between the (medication-adjusted) SBP and DBP. Covariates used in the analyses were measured at the same visit as the blood pressure measurements.
We calculated regression residuals for medicationadjusted SBP, DBP, and PP after adjusting for age, age 2 , sex, body mass index (BMI), field center (if data within a study were collected from multiple centers), case-control status (WHI only; grouped all stroke and VTE cases together), and principal components (three PCs for individuals of European ancestry and ten PCs for individuals of African or East Asian ancestry, or Hispanics). Because the residuals are approximately normally distributed, no phenotype transformation was performed on any of the studies (Online Resource Figs. 1-4) . Residuals of these regressions were used as the phenotype for association analysis.
Statistical analyses
Instead of pooling all the data together, we analyzed each of the 19 ancestry-and study-specific cohorts separately and meta-analyzed the results using Fisher's method to reduce potential bias with study design heterogeneity (Fig. 1) . We conducted single SNP and gene-based associations for all protein-coding genes within the linkage region on 16p13 (chr16:2737103-16223464) using the software EPACTS (EPACTS: Efficient and Parallelizable Association Container Toolbox 2016). A kinship matrix was generated for each of the ten TOPMed studies analyzed using EPACTS (EPACTS: Efficient and Parallelizable Association Container Toolbox 2016) and these were incorporated into all of the association analyses to adjust for within-study relatedness.
In the stage I discovery analysis, using TOPMed CFS-EA WGS data, we selected for variants in protein-coding genes that segregate at least two times in at least 1 of the 11 identified families contributing to the linkage evidence (He et al. 2017) . Within the linkage region, we first filtered the variants by protein-coding genes and consequently excluded the intergenic regions. The gene region is defined by Ensembl Variant Effect Predictor (Ensembl Variation-Calculated variant consequences 2018) as a part of the functional annotations curated by WGSA (Liu et al. 2016b) , which is provided by the TOPMed DCC. These variants are hereafter referred to as linkage-based selected variants and they were divided into two groups using WGSA (Liu et al. 2016b) functional annotations for single variant and gene-based association tests: (a) functional coding variants that result in an amino acid change and (b) the remaining non-coding variants. The functional coding variants include the following classifications: inframe deletions/insertions, exon loss variant (deletion of an exon), frameshift variant, initiator codon variant non-canonical start codon, splice acceptor variant, splice region variant, start lost variant, stop lost/gained variant, and missense variant. The remaining non-coding variants include any classifications that are not listed previously except for intergenic variants; however, this subset of variants also includes synonymous variants, which although coding, do not lead to amino acid changes. The majority of the non-coding variants are intronic variants.
Single variant association tests for SNPs and indels were performed for all linkage-based selected variants in the linkage region using the Efficient Mixed-Model Association eXpedited (EMMAX) test for quantitative traits (Kang et al. 2010) . Gene-based tests for SNPs and indels were performed using the variable-threshold burden test (burdenVT) (Price et al. 2010) , combined multivariate and collapsing burden test (burdenCMC) (Li and Leal 2008) , and mixed-model sequence kernel association test (SKAT) (Wu et al. 2011 ). We incorporated linkage-based selected functional coding variants with any MAF and non-coding rare variants (MAF < 1%). Although the focus of our study is on rare and low-frequency variants, we included common functional coding variants in the analysis as they may have important biological implications. We imposed an additional filter for non-coding variants using the CADD Phred-like score (Liu et al. 2016b ). We used a threshold of CADD Phred-like score > 10 to retain the top 10% most deleterious variants for analysis. In the stage II replication analysis, we replicated variants across studies using the same set of variants identified from CFS-EA, regardless of their availability or study-specific MAF in the independent replication studies. For the gene-based tests, meta-analyses of 6 EA replication cohorts and 18 multi-ancestry replication cohorts were calculated using Fisher's combined p value method. Initially, we analyzed functional coding and rare non-coding variants separately under the assumption that the functional coding variants are more likely to have a unidirectional effect, whereas non-coding variants are likely to have bi-directional effects on the BP traits. However, to minimize potential issues with multiple comparisons, in the stage II independent replication analysis, we further combined functional coding and non-coding variants for genebased analysis, and the final reported genes were based on this analysis. The significance level for stage II p values was determined by two independent traits for SBP, DBP, and PP, 25 unique genes tested for the analysis, and three gene-based tests, resulting in a conservative threshold (p = 3.3 × 10 −4 ). While the genetic correlation between SBP and DBP is high (0.93-0.98), the genetic correlation between DBP and PP is low (0.05) (van Rijn et al. 2007 ).
GTEx V6p cis-eQTL gene expression data and covariates were downloaded from the GTEx Portal (https ://www. gtexp ortal .org/home/datas ets). Imputed genotype data (N = 450) were downloaded from dbGaP. From this dataset, we performed gene-based association analysis between gene expression and linkage-based selected variants in a corresponding gene in the currently available 44 tissues (including two cell lines). We used the residual of the gene expression level as the phenotype, after adjusting for sex, platform, PCs 1-3, and tissue-specific latent factors inferred by GTEx using the PEER method (Stegle et al. 2012) . The analyzed variants were limited to variants replicated across studies, where we aggregated linkage-based selected functional coding variants and rare non-coding variants identified from CFS-EA. For the imputed genotype data, the rare variant filters imposed by GTEx (maf05, maf01) were removed to include as many linkage-based selected rare variants as possible for this analysis. Imputation info score and Hardy-Weinberg equilibrium filters were kept for QC.
While some variants in the promoter and non-coding regulatory region can be captured by our defined gene units, it is possible that many functionally important intergenic variants are left out by our variant selection criteria and must be supplemented with regulatory annotations. Enhancer elements were defined by GeneHancer, a database that integrates enhancers reported from the Encyclopedia of DNA Elements (ENCODE), the Ensembl regulatory build, and Functional ANnoTation Of the Mammalian genome (FANTOM) project, and the VISTA Enhancer Browser (Fishilevich et al. 2017) . We only included enhancer elements that were denoted as "elite" on GeneCards (http:// www.genec ards.org/), defined as enhancer-gene relations reflecting both a high-likelihood enhancer definition and a strong enhancer-gene association. Gene-enhancer associations were generated by integrating multiple sources of information, including expression quantitative trait loci (eQTLs), enhancer RNA (eRNA) co-expression, transcription factor (TF) co-expression, capture Hi-C (CHi-C), and gene target distance. The analysis groups were aggregated by gene units and each group consists of linkage-based selected functional coding variants and rare non-coding variants within the reported enhancer element. We performed genebased association analysis using our defined variant sets and BP traits for each gene.
Results
Descriptive characteristics are provided for all subjects (Online Resource Table 1 ). Our previous study identified a linkage region on 16p13 with a maximum LOD score of 2.81 (He et al. 2017) . In children, blood pressure increases with age and the normal blood pressure ranges are different from those of adults. Thus, we updated the 2 LOD-score drop region after removing individuals under 18 years old (MLOD 2.54), resulting in a targeted region chr16:2737103-16223464.
It is important to verify whether common variants in the linkage region could be driving the linkage or association analysis. To the best of our knowledge, only three common variants have been identified through BP GWAS in the linkage region on 16p13: rs35450617 (g.6839674T>G), rs12921187 (g.4893018T>G), rs3915425 (g.15818687T>C) (Evangelou et al. 2018) . These three variants reside within RBFOX1, PPL, and MYH11, respectively. We performed conditional association analysis in the discovery cohort by including these three variants as covariates. These three SNPs (MAFs > 0.27 for all) and were not associated with any BP trait in CFS-EA, suggesting that they have minimal effect on the linkage and association analyses in this study.
In CFS-EA linkage analysis with exome array data, we observed 11 families with family-specific LOD score (fsLOD) ≥ 0.1 at the most significant SNP (rs6501060; g.8041950T>C), regardless of the inclusion of participants under 18. In CFS-EA TOPMed WGS data, we used the same 11 families and selected for variants in protein-coding genes that segregate at least twice in at least one of these families. The size of these 11 families ranges from 2 to 11 individuals, with a total of 72 individuals. Our selection of variants using family information resulted in 76 genes with functional coding variants and 131 genes with remaining non-coding variants. From the CFS-EA discovery cohort, we observed 20 genes containing functional coding variants with at least one gene-based test p value < 0.05 (Online Resource Table 2 ) and 8 genes containing non-coding variants (MAF < 1%, CADD > 10) with at least one gene-based test p value < 0.05. Three genes overlap between these two groups. The linkage-based selected functional coding and 1 3 non-coding variants from these 25 unique candidate genes (burden or SKAT p < 0.05) in CFS-EA (stage I) were carried forward for stage II replication analysis in ten independent, multi-ancestry TOPMed studies (Online Resource Tables 3,  4 , and 5).
We initially analyzed functional coding and rare noncoding variants separately in the replication gene-based analysis. Our previously identified RBFOX1 gene association remains nominally significant (SBP, p = 0.021 for burdenCMC) in the meta-analysis of six EuropeanAmerican cohorts involving functional variants within 20 genes. We observed three additional genes (CLUAP1, TRAP1, and SLX4) with functional coding variants that are nominally associated with BP traits (Online Resource Table 3 ). The association evidence became less significant when cohorts of African and East Asian ancestry and Hispanics were included (Online Resource Table 3 ), which is expected given many of these variants are not present in those cohorts. For non-coding variants in the eight genes carried forward for independent replication, we observed four unique genes (MYH11, MTRNR2L4, RBFOX1, and SLX4) that were nominally significant in the meta-analysis of six EA cohorts (Online Resource Table 4 ), but none of the four genes pass multiple testing. Again, adding cohorts other than European Americans weakened the association evidence for the same reason as before.
Next, we aggregated linkage-based selected functional coding variants and non-coding variants in all 25 unique genes carried forward for replication (Online Resource  Table 5 ). In particular, we focused on MTRNR2L4, RBFOX1, and SLX4 because they showed the most significant association evidence (Table 1) . Since there were no linkage-based selected functional coding variants in MTRNR2L4, the aggregated gene-based test had the same results as the noncoding variant gene-based test for this gene. We observed an improvement in the association evidence for both RBFOX1 and SLX4 after aggregating both functional coding and noncoding variants for gene-based analysis. In the EA replication cohorts, SLX4 variants are significantly associated with PP (p = 2.19 × 10 −4 for burdenVT), after Bonferroni correction, which accounts for 25 genes, three tests, and two independent traits for SBP, DBP, and PP. We further explored the tissue-specific gene expression associations using GTEx V6p data for the RBFOX1, SLX4, and MTRNR2L4. We investigated the gene expression levels of these three genes among individuals with imputed genotyping array data. Although we analyzed all of the currently available tissues, there are many systems of the human body that affect BP so we only presented the association evidence for a few tissues that may be relevant to BP, including the brain, heart, and blood vessels (Table 2 ). For tissue-specific gene-based analysis, we analyzed functional coding and noncoding variants replicated across studies and tested for genebased association in all available tissues. Gene expression of RBFOX1 is available in 29 tissues. The linkage-based selected variants of RBFOX1 were associated with tissues in the nervous system, including the hypothalamus (p = 0.040 for burdenCMC), putamen (p = 0.014 for burdenVT), and tibial nerve (p = 4.35 × 10 −5 for burdenCMC). SLX4 gene expression levels are available in 44 tissues and linkagebased selected variants within this gene are associated with several brain and heart tissues, including the cerebellar hemisphere (p = 0.027 for SKAT), hypothalamus (p = 0.033 for SKAT), coronary artery (p = 0.011 for burdenCMC), and heart atrial appendage (p = 0.028 for burdenCMC). For MTRNR2L4, none of the linkage-based selected variants can be found in the imputed genotyping array data; thus, there were no eligible variants for analysis.
To identify potential regulatory variants that fall outside of the genes of interest (e.g. intergenic variants), we used GeneHancer to detect candidate enhancer elements for RBFOX1, SLX4, and MTRNR2L4 (Fishilevich et al. 2017) . For each gene, we aggregated linkage-based selected functional coding variants of the enhancer gene target with available non-coding variants (MAF < 5%; CADD > 10) within these enhancer elements. Then we conducted group-wise burden and SKAT tests for each gene (Table 3) . As expected, most of the non-coding variants in enhancer elements were intergenic or intragenic enhancers. For these three genes, there was no overlap between variants within enhancer elements and linkage-based selected non-coding variants identified from CFS-EA. Because the GeneHancer data are based on multiple tissues, tissue-specific results are unavailable. We focused on the meta-analysis for all seven European American cohorts (N = 18,420). We found that variants in RBFOX1, SLX4, and MTRNR2L4 were associated with all three BP traits (p < 0.05), before but not after adjusting for multiple comparisons. The association evidence weakens after adding cohorts of African and East Asian ancestry and Hispanics (results not shown). 
Discussion
This study demonstrates the added power and promise of linkage evidence when investigating low-frequency and rare variants in complex diseases such as hypertension. Previously, another study (Roeder et al. 2006 ) presented a method that uses linkage data to weight the association p values. They implemented an exponential weighting scheme or cumulative weighting scheme using LOD scores. The samples used in linkage analysis and association analysis are independent. However, the weighting approach by Roeder et al. does not work for rare variant analysis within a gene or locus because there is no variation of the LOD scores. In our study, we weight the contribution of a rare variant to linkage evidence rather than directly weighting the LOD scores. Thus, our approach can be applied to rare variant analysis in a gene or locus. Overall, our association evidence is stronger in European ancestry cohorts compared to African and East Asian ancestry cohorts and Hispanics. This finding is not surprising given rare variants were initially identified from European American families, increasing the probability that linkage-based selected variants will be monomorphic or extremely rare in other ancestries or ethnicity. The majority of our study subjects are of European ancestry (61%). We were able to verify the association between RBFOX1 and BP traits as well as identify a novel gene SLX4.
For RBFOX1, SLX4, and MTRNR2L4, we looked at characteristics of CFS-EA subjects and families who carried the linkage-based selected variants used in this study. Our previous analysis of RBFOX1 was limited to linkagebased selected functional coding variants in the exome array data (He et al. 2017) . Using TOPMed WGS data, we were able to further investigate the non-coding variants in RBFOX1. Summary characteristics for CFS-EA carriers of linkage-based selected variants are provided (Online Resource Table 6 ). Using family information, we identified two rare (MAF < 5%) and one common functional coding variants. The common variant is a splice region variant and the two rare variants are missense variants. For both functional coding rare variants of RBFOX1 (rs149974858 [p.Pro38Ala] and rs145873257 [p.Gly374Ser]), the directions of effect from meta-analysis of all 19 cohorts are negative for all three BP traits (Online Resource Table 7) , consistent with a protective effect. All three carriers of rs149974858 reside within one family and were morbidly obese with a median BMI of 62.37. They had a median BP measure (SBP/DBP) of 115/84 mm Hg and median residuals of − 27.05 and − 2.38 for SBP and DBP, respectively. Given their elevated BMI, the blood pressure measurements of these three carriers were lower than expected, which deviates from the positive correlation between BMI and BP found in previous studies (Droyvold et al. 2005; Dua et al. 2014) . Nine carriers of rs145873257 reside in three families. They were overweight (median BMI 28.35) and had negative median residuals for BP respectively) . Again, this variant showed a protective effect on BP given their high BMI. On the other hand, non-coding variants had bidirectional effects with nearly half of the variants having a protective effect and the rest having a deleterious effect for all three BP traits (Online Resource Table 7 ). This is consistent with our gene-based meta-analysis, which shows a significant association in SKAT for non-coding variants (Online Resource Table 4 ).
In CFS-EA, we identified ten functional coding variants and three non-coding rare variants in SLX4 (Online Resource  Tables 6 and 9 ). All ten functional variants are missense variants and only one of them is rare (rs140051968; p.Ser1342Gly; MAF = 0.0038). Out of the nine common functional coding variants, seven variants are in high LD (r 2 > 0.9) with each other. However, excluding variants in high LD in the gene-based tests barely changes the EA metaanalysis association results functional coding variants only: p = 0.005 for burdenVT in PP; functional coding and rare non-coding variants together: p = 2.5 × 10 −4 for burdenVT in PP. In the single SNP meta-analysis, rs140051968 is presented in four EA cohorts and it had a positive direction of effect for all three BP traits, suggesting a deleterious effect that elevates BP. In CFS-EA, three subjects within the same family carry rs140051968. They have a median BP of 136/80 mmHg with a median BMI of 25, which indicates the carriers have an elevated BP without being overweight or obese. For the three non-coding variants in SLX4, the carriers are obese (median BMI > 30 for carriers of each SNP) and have an elevated BP (median SBP/ DBP > 146/88 mmHg), which is expected based on published literature (Droyvold et al. 2005; Dua et al. 2014 ). The gene SLX4 plays an important role in DNA double-strand break repair (Yamamoto et al. 2011) . Based on GTEx gene expression data, it is highly expressed in the cerebellum, a region implicated in BP control through the cerebellar adrenomedullary system (Figueira and Israel 2018) .
We identified two non-coding rare variants in MTRNR2L4 (rs146514363 [n.84+2329C>T] and rs540895452 [n.84+7135G>A]) from CFS-EA. The SNP rs146514363 (MAF = 0.0038) is presented in three subjects (two families) and can be found in 11 out of 16 replication cohorts and all 6 EA replication cohorts. There are three carriers for rs540895452 (MAF = 0.0038) and all of them are in the same family. This variant is only presented in 4 out of 16 replication cohorts, all of which are European. Because each gene-based test must have at least two variants, gene-based meta-analysis can only be done in EA cohorts. Similar to rs140051968 in SLX4, carriers of either rs146514363 or rs540895452 have elevated BP (median BP > 132/80) without being obese (median BMI < 27). MTRNR2L4 plays a role in neuroprotective and anti-apoptotic factor (Bodzioch et al. 2009 ), but its role in BP regulation remains unclear.
Although our statistical evidence for rare variants in MYH11 is modest, there is biological and clinical evidence that MYH11 could impact the risk of cardiovascular disease. MYH11 encodes the protein myosin-11, which is a component of the myosin heavy chain in smooth muscle. Mutations in MYH11 have been reported to cause thoracic aortic aneurysms and/or dissections (Takeda et al. 2015; Zhu et al. 2006) . High blood pressure and high cholesterol are both risk factors for atherosclerosis and consequently may lead to thoracic aortic aneurysm.
Our study illustrates some important implications. We observed that rare variants are more likely to be ancestry specific. In the stage II replications, we found that many variants identified from the European American discovery cohort are monomorphic in other ancestries. It is possible that different variants within the same genes may be associated with BP traits in different ancestral populations. Thus, we did gene-based analyses for MTRNR2L4, RBFOX1, and SLX4 in the replication cohorts using variants passing the following criteria in each cohort: any functional coding variants and rare non-coding variants with cohort-specific MAF < 1% and CADD > 10. All singletons (i.e. allele count = 1 within the cohort) have been removed from each cohort prior to genebased analysis. We used these criteria as they are similar to the selection criteria we used previously with CFS-EA for association analysis. Based on these results, we noticed an improvement in the association evidence between RBFOX1 variants and SBP in the EA (burdenCMC p = 3.7 × 10 −4 ) and multi-ethnic (burdenCMC p = 0.004) meta-analysis (Online Resource Table 8 ). The association evidence in EA is driven by FHS (SKAT p = 0.010), GeneSTAR-EA (burdenCMC p = 0.001), and WHI-EA (burdenCMC p = 0.007), which account for over half of the EA replication samples (12,106 out of 18,025 individuals). FHS and GeneSTAR-EA are both family studies, in which rare variants can be enriched. There are a number of coding variants identified in these three cohorts that are not found in CFS-EA: 18 for FHS, 6 for GeneSTAR, and 22 for WHI. Overall, these findings suggest that there are BP-associated variants within RBFOX1 that are absent in CFS-EA. This conclusion provides further evidence supporting our previous study (He et al. 2017) , which states that RBFOX1 variants are associated with BP traits in European Americans. In non-European samples, SLX4 variants are associated with PP (SKAT p = 0.037) in African Americans before but not after Bonferroni correction.
When we looked at characteristics of CFS-EA carriers for the analyzed variants, individuals who are overweight or obese did not consistently have elevated BP or more severe hypertension, which departs from the expected positive correlation between BMI and BP. Due to limited information on comorbidities, we were unable to further examine the clinical characteristics of these carriers.
There are a few limitations in this study. First, BP measurement method and procedure varied among studies. Secondly, the gene expression data for TOPMed subjects were unavailable at the time of the study. Therefore, the gene expression analysis was done using GTEx subjects with a relatively small sample size. Gene expression data for TOPMed cohorts may become available in the future and allow us to conduct further analysis on the cellular transcriptome. Thirdly, the discovery sample size is very small (N = 395 in CFS-EA), although the exome array data with the linkage evidence had more complete families with additional individuals (N = 517). Carrying out the same study in much larger discovery studies may lead to additional discoveries. Finally, we also had limited data on Hispanics and individuals of African and East Asian ancestry.
In summary, we performed association analysis of functional coding and rare non-coding variants within the 16p13 region using 30,383 subjects from the TOPMed WGS project. To improve power, we utilized linkage findings, enabling the discovery of a novel gene SLX4 and replication of a previously identified gene RBFOX1 for BP traits. While these variants may only explain a small proportion of BP variation at the population level, some variants could substantially impact blood pressure in individual carriers and may help identify pharmacological targets; thus, potentially making it a promising approach for personalized medicine. This study has shown that family information can be used to help discover genes and variants that may be missed by GWAS in isolation.
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